Abstract
Bipolar II disorder (BP-II) is defined, by DSM-IV, as recurrent episodes of depression and hypomania. Hypomania, according to DSM-IV, requires elevated (euphoric) and/or irritable mood, plus at least three of the following symptoms (four if mood is only irritable): grandiosity, decreased need for sleep, increased talking, racing thoughts, distractibility, overactivity (an increase in goal-directed activity), psychomotor agitation and excessive involvement in risky activities. This observable change in functioning should not be severe enough to cause marked impairment of social or occupational functioning, or to require hospitalisation. The distinction between BP-II and bipolar I disorder (BP-I) is not clearcut. The symptoms of mania (defining BP-I) and hypomania (defining BP-II) are the same, apart from the presence of psychosis in mania, and the distinction is based on the presence of marked impairment associated with mania, i.e. mania is more severe and may require hospitalisation. This is an unclear boundary that can lead to misclassification; however, the fact that hypomania often increases functioning makes the distinction between mania and hypomania clearer.
BP-II depression can be syndromal and subsyndromal, and it is the prominent feature of BP-II. It is often a mixed depression, i.e. it has concurrent, usually subsyndromal, hypomanic symptoms. It is the depression that usually leads the patient to seek treatment.
DSM-IV bipolar disorders (BP-I, BP-II, cyclothymic disorder and bipolar disorder not otherwise classified, which includes very rapid cycling and recurrent hypomania) are now considered to be part of the ‘bipolar spectrum’. This is not included in DSM-IV, but is thought to also include antidepressant/substance-associated hypomania, cyclothymic temperament (a trait of highly unstable mood, thinking and behaviour), unipolar mixed depression and highly recurrent unipolar depression.
BP-II is underdiagnosed in clinical practice, and its pharmacological treatment is understudied. Underdiagnosis is demonstrated by recent epidemiological studies. While, in DSM-IV, BP-II is reported to have a lifetime community prevalence of 0.5%, epidemiological studies have instead found that it has a lifetime community prevalence (including the bipolar spectrum) of around 5%. In depressed outpatients, one in two may have BP-II. The recent increased diagnosing of BP-II in research settings is related to several factors, including the introduction of the use of semi-structured interviews by trained research clinicians, a relaxation of diagnostic criteria such that the minimum duration of hypomania is now less than the 4 days stipulated by DSM-IV, and a probing for a history of hypomania focused more on overactivity (increased goal-directed activity) than on mood change (although this is still required for a diagnosis of hypomania).
Guidelines on the treatment of BP-II are mainly consensus based and tend to follow those for the treatment of BP-I, because there have been few controlled studies of the treatment of BP-II. The current, limited evidence supports the following lines of treatment for BP-II. Hypomania is likely to respond to the same agents useful for mania, i.e. mood-stabilising agents such as lithium and valproate, and the second-generation antipsychotics (i.e. olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole). Hypomania should be treated even if associated with overfunctioning, because a depression often soon follows hypomania (the hypomania-depression cycle). For the treatment of acute BP-II depression, two controlled studies of quetiapine have not found clearcut positive effects. Naturalistic studies, although open to several biases, have found antidepressants in acute BP-II depression to be as effective as in unipolar depression; however, one recent large controlled study (mainly in patients with BP-I) has found antidepressants to be no more effective than placebo. Results from naturalistic studies and clinical observations on mixed depression, while in need of replication in controlled studies, indicate that antidepressants may worsen the concurrent intradepression hypomanic symptoms. The only preventive treatment for both depression and hypomania that is supported by several, albeit older, controlled studies is lithium. Lamotrigine has shown some efficacy in delaying depression recurrences, but there have also been several negative unpublished studies of the drug in this indication.
Similar content being viewed by others
References
Angst J. The bipolar spectrum. Br J Psychiatry 2007; 190: 189–91
Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–7
Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261–9
Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs bipolar II disorders. Int J Neuropsychopharmacol 2003; 6: 127–37
Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord 2003; 73: 19–32
Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62: 1322–30
Ostacher MJ. The evidence for antidepressant use in bipolar depression. J Clin Psychiatry 2006; 67Suppl. 11: 18–21
Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: Livingstone E & S, 1921
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text rev. Washington (DC): American Psychiatric Association, 2000
World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization, 1992
Angst J, Gamma A, Benazzi F, et al. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003; 73: 133–46
Akiskal HS, Azorin JM, Hantouche EG. Proposed multidimensional structure of mania: beyond the euphoric-dysphoric dichotomy. J Affect Disord 2003; 73: 7–18
Benazzi F. Factor structure of recalled DSM-IV hypomanic symptoms of bipolar II disorder. Compr Psychiatry 2004; 45: 441–6
Koukopoulos A. Ewald Hecker’s description of cyclothymia as a cyclical mood disorder: its relevance to the modern concept of bipolar II. J Affect Disord 2003; 73: 199–205
Sedler MJ. Falret’s discovery: the origin of the concept of bipolar affective illness. Am J Psychiatry 1983; 140: 1127–33
Benazzi F. Is there a continuity between bipolar and depressive disorders? Psychother Psychosom 2007; 76: 70–6
Ghaemi SN, Baldessarini RJ. The manic-depressive spectrum and mood stabilization: Kraepelin’s ghost. Psychother Psychosom 2007; 76: 65–9
Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970; 126: 983–7
Hantouche EG, Angst J, Akiskal HS. Factor structure of hypomania: interrelationships with cyclothymia and the soft bipolar spectrum. J Affect Disord 2003; 73: 39–47
Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005; 88: 217–33
Cassidy F, Forest K, Murry E, et al. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry 1998; 55: 27–32
Bauer MS, Crits-Christoph P, Ball WA, et al. Independent assessment of manic and depressive symptoms by self-rating: scale characteristics and implications for the study of mania. Arch Gen Psychiatry 1991; 48: 807–12
Dilsaver SC, Chen YR, Shoaib AM, et al. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am J Psychiatry 1999; 156: 426–30
Swann AC, Janicak PL, Calabrese JR, et al. Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants. J Affect Disord 2001; 67: 123–32
Coryell W, Endicott J, Maser JD, et al. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995; 152: 385–90
Akiskal HS, Maser JD, Zeller PJ, et al. Switching from ‘unipolar’ to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995; 52: 114–23
Duffy A, Grof P, Robertson C, et al. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000; 61: 630–7
Joyce PR, Doughty CJ, Wells JE, et al. Affective disorders in the first-degree relatives of bipolar probands: results from the South Island Bipolar Study. Compr Psychiatry 2004; 45: 168–74
Benazzi F. Bipolar II disorder family history using the family history screen: findings and clinical implications. Compr Psychiatry 2004; 45: 77–82
Gershon ES, Hamovit J, Guroff JJ, et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch Gen Psychiatry 1982; 39: 1157–67
Heun R, Maier W. The distinction of bipolar II disorder from bipolar I and recurrent unipolar depression: results of a controlled family study. Acta Psychiatr Scand 1993; 87: 279–84
Akiskal HS, Akiskal KK, Haykal RF, et al. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 2005; 85: 3–16
Akiskal HS, Akiskal KK, Lancrenon S, et al. Validating the bipolar spectrum in the French national epidep study: overview of phenomenology and relative prevalence of its clinical prototypes. J Affect Disord 2006; 96: 197–205
Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent (major) depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord 2006; 92: 45–54
Benazzi F. Challenging the unipolar-bipolar division: does mixed depression bridge the gap? Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 97–103
Cassano GB, Frank E, Miniati M, et al. Conceptual underpinnings and empirical support for the mood spectrum. Psychiatr Clin North Am 2002; 25(4): 699–712
Cassano GB, Rucci P, Frank E, et al. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 2004; 161(7): 1264–9
McElroy SL, Keck Jr PE, Pope Jr HG, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992; 149: 1633–44
Benazzi F. Bipolar disorder: focus on bipolar II disorder and mixed depression. Lancet 2007; 369: 935–45
Bauer MS, Simon GE, Ludman E, et al. “Bipolarity” in bipolar disorder: distribution of manic and depressive symptoms in a treated population. Br J Psychiatry 2005; 187: 87–8
Sato T, Bottlender R, Schroter A, et al. Frequency of manic symptoms during a depressive episode and unipolar ‘depressive mixed state’ as bipolar spectrum. Acta Psychiatr Scand 2003; 107: 268–74
Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord 2003; 73: 113–22
Maj M, Pirozzi R, Magliano L, et al. Agitated ‘unipolar’ major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry 2006; 67: 712–9
Koukopoulos K, Sani G, Albert MJ, et al. Agitated depression: spontaneous and induced. In: Marneros A, Goodwin F, editors. Bipolar disorders. Cambridge: Cambridge University Press, 2005: 157–86
Perugi G, Akiskal HS, Micheli C, et al. Clinical characterization of depressive mixed state in bipolar-I patients: Pisa-San Diego collaboration. J Affect Disord 2001; 67: 105–14
Maj M, Pirozzi R, Magliano L, et al. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am J Psychiatry 2003; 160: 2134–40
Benazzi F. Mixed states in bipolar II disorder: should full hypomania always be required? Psychiatry Res 2004; 127: 247–57
Biondi M, Picardi A, Pasquini M, et al. Dimensional psychopathology of depression: detection of an ‘activation’ dimension in unipolar depressed outpatients. J Affect Disord 2005; 84: 133–9
Serretti A, Olgiati P. Profiles of “manic” symptoms in bipolar I, bipolar II and major depressive disorders. J Affect Disord 2005; 84: 159–66
Suppes T, McElroy SL, Altshuler LL, et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Bipolar Treatment Network: a gender-specific phenomenon. Arch Gen Psychiatry 2005; 62: 1089–96
Akiskal HS, Benazzi F. Toward a clinical delineation of dysphoric hypomania: operational and conceptual dilemmas. Bipolar Disord 2005; 7: 456–64
Sato T, Bottlender R, Kleindienst N, et al. Irritable psychomotor elation in depressed inpatients: a factor validation of mixed depression. J Affect Disord 2005; 84: 187–96
Benazzi F. Bipolar II disorder and major depressive disorder: continuity or discontinuity? World J Biol Psychiatry 2003; 4: 166–71
Dikeos DG, Wickham H, McDonald C, et al. Distribution of symptom dimensions across Kraepelinian divisions. Br J Psychiatry 2006; 189: 346–53
Benazzi F. Does age at onset support a dimensional relationship between bipolar II disorder and major depressive disorder? World J Biol Psychiatry 2007; 31: 944–51
Benazzi F. Does temperamental instability support a continuity between bipolar II disorder and major depressive disorder? Eur Psychiatry 2006; 21: 274–9
Benazzi F. A continuity between bipolar II depression and major depressive disorder? Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1043–50
Benazzi F, Akiskal HS. A downscaled practical measure of mood lability as a screening tool for bipolar II. J Affect Disord 2005; 84: 225–32
Akiskal HS, Hantouche EG, Allilaire JF. Bipolar II with and without cyclothymic temperament: “dark” and “sunny” expressions of soft bipolarity. J Affect Disord 2003; 73: 49–57
Benazzi F. Borderline personality-bipolar spectrum relationship. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 68–74
Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr Scand 2004; 110: 401–7
Hantouche EG, Akiskal HS. Toward a definition of a cyclothymic behavioral endophenotype: which traits tap the familial diathesis for bipolar II disorder? J Affect Disord 2006; 96: 233–7
Akiskal HS, Hantouche EG, Allilaire JF, et al. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord 2003; 73: 65–74
Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537–47
Moller HJ, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 2006; 256: 1–16
Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421–33
Benazzi F, Akiskal HS. Biphasic course in bipolar II outpatients: prevalence and clinical correlates of a cyclic pattern described by Baillarger and Falret in hospitalised patients in 1854. J Affect Disord 2006; 96: 183–7
Perugi G, Toni C, Travierso MC, et al. The role of cyclothymia in atypical depression: toward a data-based reconceptualization of the borderline-bipolar II connection. J Affect Disord 2003; 73: 87–98
Ghaemi SN, Ko JY, Goodwin FK. “Cade’s disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47: 125–34
Benazzi F. Family history validation of a definition of mixed depression. Compr Psychiatry 2005; 46: 159–66
Regeer EJ, Krabbendam L, de Graaf R, et al. A prospective study of the transition rates of subthreshold (hypo)mania and depression in the general population. Psychol Med 2006; 36: 619–27
Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18: 141–53
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19
Regeer EJ, ten Have M, Rosso ML, et al. Prevalence of bipolar disorder in the general population: a reappraisal study of the Netherlands Mental Health Survey and Incidence Study. Acta Psychiatr Scand 2004; 110: 374–82
Goldney RD, Fisher LJ, Grande ED, et al. Bipolar I and II disorders in a random and representative Australian population. Aust N Z J Psychiatry 2005; 39: 726–9
Jacobi F, Wittchen HU, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004; 34: 597–611
Schaffer A, Cairney J, Cheung A, et al. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry 2006; 51: 9–16
ten Have M, Vollebergh W, Bijl R, et al. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 2002; 68: 203–13
Kessler RC, Akiskal HS, Angst J, et al. Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3. 0. J Affect Disord 2006; 69: 259–69
Szadoczky E, Papp Z, Vitrai J, et al. The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998; 50: 153–62
Kessler RC, Berglund P, Dernier O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602
Faravelli C, Rosi S, Alessandra Scarpato M, et al. Threshold and subthreshold bipolar disorders in the Sesto Fiorentino Study. J Affect Disord 2006; 94: 111–9
Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123–31
Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001; 158: 1265–70
Angst J, Sellaro R, Stassen HH, et al. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 2005; 84: 149–57
Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157: 1873–5
Angst J, Dobler-Mikola A, Binder J. The Zurich study: a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes: I. Problem, methodology. Em-Arch Psychiatry Neurol Sci 1984; 234: 13–20
Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 43: 163–6
Smith DJ, Harrison N, Muir W, et al. The high prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward an innovative diagnostic framework. J Affect Disord 2005; 84: 167–78
Rybakowski JK, Suwalska A, Lojko D, et al. Bipolar mood disorders among Polish psychiatric outpatients treated for major depression. J Affect Disord 2005; 84: 141–7
Benazzi F, Akiskal H. The duration of hypomania in bipolar-II disorder in private practice: methodology and validation. J Affect Disord 2006; 69: 189–96
Benazzi F. Diagnosis of bipolar II disorder: a comparison of structured versus semistructured interviews. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 985–91
Simpson SG, McMahon FJ, McInnis MG, et al. Diagnostic reliability of bipolar II diagnosis. Arch Gen Psychiatry 2002; 59: 736–40
Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 2003; 73: 33–8
Akiskal HS, Benazzi F. Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. J Clin Psychiatry 2005; 66: 914–21
First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV). Washington (DC): American Psychiatric Press, 1997
Benazzi F. Challenging DSM-IV criteria for hypomania: diagnosing based on number of no-priority symptoms. Eur Psychiatry 2007; 22: 99–103
Benazzi F. Is overactivity the core feature of hypomania in bipolar II disorder? Psychopathology 2007; 40: 54–60
Faedda GL, Baldessarini RJ, Glovinsky IP, et al. Pediatric bipolar disorder: phenomenology and course of illness. Bipolar Disord 2004; 6: 305–13
Birmaher B, Axelson D, Strober M, et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63: 175–83
Geller B, Tillman R, Bolhofner K, et al. Controlled, blindly rated, direct-interview family study of a prepubertal and early-adolescent bipolar I disorder phenotype: morbid risk, age at onset, and comorbidity. Arch Gen Psychiatry 2006; 63: 1130–8
Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63: 1139–48
Dilsaver SC, Benazzi F, Akiskal HS. Mixed states: the most common outpatient presentation of bipolar depressed adolescents? Psychopathology 2005; 38: 268–72
Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord 2000; 2 (3 Pt 2): 281–93
Verhulst FC, van der Ende J, Ferdinand RF, et al. The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 1997; 54: 329–36
Bottlender R, Sato T, Kleindienst N, et al. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J Affect Disord 2004; 78: 149–52
Goldberg JF, Truman CJ, Fordis J, et al. Antidepressant use during mixed states: naturalistic outcome data from the STEP-1000 [abstract]. Neuropsychopharmacology 2004; 29: S144
Benazzi F. Which could be a clinically useful definition of depressive mixed state? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1105–11
Benazzi F. Bipolar II depressive mixed state: finding a useful definition. Compr Psychiatry 2003; 44: 21–7
Benazzi F. Bipolar family history of the hypomanic symptoms and dimensions of mixed depression. Compr Psychiatry 2005; 46: 399–404
Benazzi F. Agitated depression: a valid depression subtype? Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1279–85
Akiskal HS, Benazzi F, Perugi G, et al. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85: 245–58
Krabbendam L, Myin-Germeys I, De Graaf R, et al. Dimensions of depression, mania and psychosis in the general population. Psychol Med 2004; 34: 1–10
Benazzi F. Unipolar depression with racing thoughts: a bipolar spectrum disorder? Psychiatry Clin Neurosci 2005; 59: 570–5
Frye MA, McElroy SL, Hellemann G, et al. Clinical correlates associated with antidepressant-related mania [abstract NR215]. Programme and abstracts of the American Psychiatric Association Annual Meeting; 2006 May 20–25; Toronto (ON)
Ghaemi SN. Re-evaluating concepts of depression: the bipolar spectrum [abstract]. New vistas in treatment-resistant depression: symposium of the American Psychiatric Association Annual Meeting. 2006 May 20–25, Toronto (ON)
Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003; 160: 4–12
US Food and Drug Administration Center for Drug Evaluation and Research. Labeling change request letter for antidepressant medication [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm [Accessed 2007 Feb 13]
Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91: 133–8
Benazzi F. Suicidal ideation and depressive mixed states. Psychother Psychosom 2005; 74: 61–2
MacKinnon DF, Potash JB, McMahon FJ, et al. Rapid mood switching and suicidality in familial bipolar disorder. Bipolar Disord 2005; 7: 441–8
Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66: 693–704
Bauer MS, Wisniewski SR, Marangell LB, et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Clin Psychiatry 2006; 67: 8–55
Benazzi F. Antidepressant-induced or clinician-induced suicidality in depression [letter]? Am J Psychiatry 2006; 163: 1644
Baldessarini R, Pompili M, Tondo L. Suicidal risk in antidepressant drug trial. Arch Gen Psychiatry 2006; 63: 246–8
McElroy SL, Kotwal R, Kaneria R, et al. Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disord 2006; 8: 596–617
Perlis RH, Beasley Jr CM, Wines Jr JD, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007; 76: 40–6
Arvilommi P, Suominen KS, Mantere OK, et al. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry 2007; 68: 102–10
Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 46: 73–7
Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313–5
Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232–9
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17
Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 435–40
Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000; 59: 225–9
Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 414–7
Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord 2006; 92: 205–14
Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124–31
Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711–22
Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60
Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranyl-cypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–6
Calabrese JR, Keck Jr PE, MacFadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60
Hirschfeld RM, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 355–62
Cookson J, Keck Jr PE, Ketter TA, et al. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007; 22: 93–100
Thase ME, MacFadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600–9
Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79–88
Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210–6
Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025–33
Manning JS, Haykal RF, Connor PD, et al. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament. J Affect Disord 2005; 84: 259–66
Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403–7
GlaxoSmithKline clinical trial register: lamotrigine studies [online]. Available from URL: http://ctr.gsk.co.uk/summary/lamotrigine/studylist.asp [Accessed 2007 Jul 18]
Benazzi F. The problem of the treatment of bipolar-II depression. Bipolar Disord 2004; 6: 440–1
Mammen OK, Pilkonis PA, Chengappa KN, et al. Anger attacks in bipolar depression: predictors and response to citalopram added to mood stabilizers. J Clin Psychiatry 2004; 65: 627–33
Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025–33
Houston JP, Ahl J, Meyers AL, et al. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or valproate. J Clin Psychiatry 2006; 67: 1246–52
Koukopoulos A. The primacy of mania. In: Akiskal HS, Tohen M, editors. Bipolar psychopharmacology. Chichester: John Wiley and Sons, 2006: 169–92
Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: the importance of the previous pattern of course of the illness. Clin Neuropharmacol 1990; 13Suppl. 1: S66–70
Ketter TA, Wang PO, Nowakowska C, et al. Treatment of acute mania in bipolar disorder. In: Ketter TA, editor. Advances in the treatment of bipolar disorder. Washington, DC: American Psychiatric Publishing, 2005: 11–55
Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001; 67: 213–9
Fieve RR, Dunner DL, Kumbaraci T, et al. Lithium carbonate prophylaxis of depression in three subtypes in primary affective disorder. Pharmakopsychiatr Neuropsychopharmakol 1976; 9: 100–7
Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders: V. A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117–20
Dunner DL, Stallone F, Fieve RR. Prophylaxis with lithium carbonate: an update. Arch Gen Psychiatry 1982; 39: 1344–5
Quitkin F, Rifkin A, Kane J, et al. Prophylactic effect of lithium and imipramine in unipolar and bipolar II patients: a preliminary report. Am J Psychiatry 1978; 135: 570–2
Peselow ED, Dunner DL, Fieve RR, et al. Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients. Am J Psychiatry 1982; 139: 747–52
Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096–104
Tondo L, Baldessarini RJ, Hennen J, et al. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998; 155: 638–45
Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14: 283–5
Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065–9
Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400
Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841–50
Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–41
Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263–71
Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003; 60: 914–20
Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108: 4–14
Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152–61
Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374–82
Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179–84
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Benazzi, F. Bipolar II Disorder. CNS Drugs 21, 727–740 (2007). https://doi.org/10.2165/00023210-200721090-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200721090-00003